Doripenem

Drugs of Today

Volumn 42, Issue 6, 2006, Pages 399-404

  Anderson, David Leif ^a  

^a Medical Information Department   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFTOBIPROLE; CILASTATIN PLUS IMIPENEM; COTRIMOXAZOLE; DAPTOMYCIN; DORIPENEM; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; PANIPENEM PLUS BETAMIPRON; VANCOMYCIN;

ABDOMINAL INFECTION; ANAEROBIC BACTERIUM; APPENDICITIS; CHOLECYSTITIS; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG ACTIVITY; DRUG POTENTIATION; DRUG SENSITIVITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PANCREATITIS; PERITONITIS; PNEUMONIA; PSEUDOMONAS AERUGINOSA; PYELONEPHRITIS; REVIEW; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA;

BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; CARBAPENEMS; CLINICAL TRIALS, PHASE III; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; RANDOMIZED CONTROLLED TRIALS;

EID: 33746225229     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.6.985634     Document Type: Review

References (31)

1. Shionogi press release dated July 25, 2005. Available at http://www.shionogi.co.jp/contents_e/investors/news/detail/e_050725.pdf. Accessed 2/27/2006.
2. Shionogi press release dated September 16, 2005. Available at http://www.shionogi.co.jp/contents_e/investors/news/detail/e_050916.pdf. Accessed Feb. 27, 2006.
3. Johnson & Johnson press release dated April 19, 2005. Available at http://www.jnj.com/news/jnj_news/20050419_082115.htm. Accessed Feb. 27, 2006.
4. Johnson & Johnson pharmaceutical pipeline. Available at http://www.jnj.com/innovations/pharma_pipeline. Accessed Feb. 27, 2006.
5. ClinicalTrials.gov. Available at http://www.clinicaltrials.gov. Accessed Feb. 27, 2006.
6. Dalhoff, A., Janjic, N., Echols, R. Redefining penems. Biochem Pharmacol 2006, 71: 1085-95.
7. Jones, R.N., Huynh, H.K., Biedenbach, D.J., Fritsche, T.R., Sader, H.S. Doripenem (S-4661), a novel carbapenem: Comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluation. J Antimicrob Chemother 2004, 54: 144-54.
8. Fritsche, T.R., Stilwell, M.G., Jones, R.N. Antimicrobial activity of doripenem (S-4661): A global surveillance report. Clin Microbiol Infect 2005, 11: 974-84.
9. Wexler, H.M., Engel, A.E., Glass, D., Li, C. In vitro activities of doripenem and comparator agents against 362 anaerobic clinical isolates. Antimicrob Agents Chemother 2005, 49: 4413-7.
10. Brown, S.D., Traczewski, M.M. Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: Tentative disc diffusion criteria and quality control. J Antimicrob Chemother 2005, 55: 944-9.
11. Ge, Y., Wikler, M.A., Sahm, D.F. et al. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother 2004, 48: 1384-96.
12. Jones, R.N., Sader, H.S., Fritsche, T.R. Comparative activity of doripenem and three other carbapenems against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005, 52: 71-4.
13. Mushtaq, S., Ge, Y., Livermore, D.M. Doripenem versus Pseudomonas aeruginosa in vitro: Activity against characterized isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases. Antimicrob Agents Chemother 2004, 48: 3086-92.
14. Jones, R.N., Huynh, H.K., Biedenbach, D.J. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004, 48: 3136-40.
15. Mushtaq, S., Ge, Y., Livermore, D.M. Comparative activities of doripenem versus isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004, 48: 1313-9.
16. Mushtaq, S., Warner, M., Kaniga, K., Ge, Y., Livermore, D.M. Bactericidal activity of doripenem versus Pseudomonas aeruginosa. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC 2005, Abst. F-1162.
17. Traczewski, M.M., Brown, S.D. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Chemother 2006, 50: 819-21.
18. Chen, Y., Garber, E., Zhao, Q. et al. In vitro activity of doripenem (S-4661) against multidrug-resistant Gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2005, 49: 2510-1.
19. Kobayashi, Y. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. J Infect Chemother 2005, 11: 259-61.
20. Mushtaq, S., Warner, M., Ge, Y., Kaniga, K., Livermore, D.M. In vitro interactions of doripenem with other antimicrobials. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC 2005, Abst. E-307.
21. Matsumoto, T., Muratani, T. Newer carbapenems for urinary tract infections. Int J Antimicrob Agents 2004, 24S: S35-8.
22. Goa, K.L., Noble, S. Panipenem/betamipron. Drugs 2003, 63: 913-25.
23. Perry, L.C.M., Ibbotson, T. Biapenem. Drugs 2002, 62: 2221-34.
24. Guignard, B., Entenza, J.M., Moreillon, P. Beta-lactams against methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol 2005, 5: 479-89 (Abst.).
25. Kosowska, K., Hoellman, D.B., Lin, G. et al. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005, 49: 1932-42.
26. Deshpande, L., Rhomberg, P.R., Fritsche, T.R. et al. Bactericidal activity of BAL9141, a novel patenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. Diagn Microbiol Infect Dis 2004, 50: 73-5 (Abst.).
27. Issa, N.C., Rouse, M.S., Piper, K.E. et al. In vitro activity of BAL9141 against clinical isolates of Gram-negative bacteria. Diagn Microbiol Infect Dis 2004, 48: 73-5.
28. Wooten, M., Bowker, K.E., Holt, H.A., MacGowan, A.P. BAL9141, a new broad-spectrum pyrrolidinone cephalosporin: Activity against clinically significant anaerobes In comparison with 10 other antimicrobials. J Antimicrob Chemother 2002, 49: 535-9.
29. Zbinden, R., Pünter, V., von Graevenitz, A. In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against Gram-negative nonfermenters. Antimicrob Agents Chemother 2002, 46: 871-4.
30. Niederman, M.S., Craven, D.E., Bonten, J.M. et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171: 388-416.
31. Solomkin, J.A., Mazuski, J.E., Baron, E.J. et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003, 37: 997-1005.